All In Biotech

Drug Trial Radar · NCT07686367

Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers

A Phase 2 Trial of IMC-F106C, a PRAME Targeted ImmTAC, in Rare Cancers

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jan 19, 2027

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
NIH
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Brenetafusp (IMC-F106C) is in a new class of immunotherapy called immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC). Brenetafusp (IMC-F106C), may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Metastatic Myxoid Liposarcoma
  • Metastatic Synovial Sarcoma
  • Unresectable Myxoid Liposarcoma
  • Unresectable Synovial Sarcoma

Interventions

  • Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106CBiological

    Given IV

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rateTime frame: Up to 8 cycles (Cycle length = 21 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.